GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » EBITDA Margin %

CTOR (Citius Oncology) EBITDA Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Citius Oncology's EBITDA for the six months ended in Sep. 2024 was $-20.57 Mil. Citius Oncology's Revenue for the six months ended in Sep. 2024 was $0.00 Mil. Therefore, Citius Oncology's EBITDA margin for the quarter that ended in Sep. 2024 was 0.00%.

Citius Oncology EBITDA Margin % Historical Data

The historical data trend for Citius Oncology's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology EBITDA Margin % Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
EBITDA Margin %
- - -

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
EBITDA Margin % - - -

Competitive Comparison of Citius Oncology's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Citius Oncology's EBITDA Margin % falls into.


;
;

Citius Oncology EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Citius Oncology's EBITDA Margin % for the fiscal year that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Sep. 2024 )/Revenue (A: Sep. 2024 )
=-20.573/0
= %

Citius Oncology's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-20.573/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology  (NAS:CTOR) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Citius Oncology EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Citius Oncology's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » EBITDA Margin %
Comparable Companies
SCYX RMTI SXTC MRMD ETST CPIX ASRT INCR INIS DRRX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Website
https://www.citiusonc.com
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.